Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicenter, randomized, placebo-controlled double-blind trial

Summary

Background:  There is a need for the development of novel non-steroidal topical drugs for the treatment of atopic dermatitis.


Objectives:  The primary objective was to evaluate the efficacy of WBI-1001 over 6 weeks of treatment of mild to severe AD.


Methods:  Patients with atopic dermatitis (AD) affecting 3-20% of their body surface area (BSA) and with an Investigator’s Global Assessment (IGA) of 2 to 4 were randomized (1:1:1) to receive placebo, 0.5% WBI-1001, or 1.0% WBI-1001 in a cream formulation applied twice daily for 6 weeks. At the end of this phase, patients receiving WBI-1001 ...

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicenter, randomized, placebo-controlled double-blind trial is a post from: Skincare

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicenter, randomized, placebo-controlled double-blind trial via BuzzBlazer.com